BNTX
BioNTech·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BNTX
Biontech Se
A company that develops personalized immunotherapies for the treatment of cancer
Biological Technology
06/02/2008
10/10/2019
NASDAQ Stock Exchange
6,772
12-31
Depository Receipts (Ordinary Shares)
An der Goldgrube 12, D-55131 Mainz, Germany
--
BioNTech SE was established on June 2, 2008. The company combines decades of pioneering research in immunology, cutting-edge therapeutic platforms, and various patient analysis and bioinformatics tools to develop individualized immunotherapies for cancer and other diseases. The company utilizes powerful new therapeutic mechanisms, utilizes a variety of biological targets, harnesses the power of each patient's immune system, and addresses the unique molecular characteristics of each patient's underlying disease.
Earnings Call
Q2/2025
Estimate EPS-2.20571
Actual EPS-1.8832
Estimate Revenue304.68M
Actual Revenue306.96M
BioNTech's 2025Q2 Earnings Call: Key Contradictions in Vaccine Demand and Oncology Focus
Aug 04,2025 02:02
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.11531
Actual EPS-0.14
Estimate Revenue1.16B
Actual Revenue1.78B
BioNTech's Q3 2025: Contradictions Emerge on R&D Strategy, BNT327 Trials, and BLA Timelines
Nov 03,2025 01:02
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BNTX has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected 0.11531, missing expectations. The chart below visualizes how BNTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BNTX has released its 2025 Q3 earnings report, with revenue of 1.78B, reflecting a YoY change of 28.48%, and net profit of -33.68M, showing a YoY change of -115.25%. The Sankey diagram below clearly presents BNTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
